Hybrid cell line formed between T4 lymphocytes and tumoral lymphoid type cells
US5550052A · kind A · utility
2Cited by
5References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 11, 1992 |
| Grant date | Aug 27, 1996 |
| Priority date | — |
| Expiry date | Sep 11, 2012 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16122
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to new purified antigens of the LAV virus. They have molecular weights of about 135,000 and 150,000 daltons. They are useful for the detection of LAV antibodies in human sera. They are produced by hybrid cell-lines resulting from the fusion of T4 lymphocytes and cells of the MOLT-4 cell line.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.